Figure 5
Effect of heparin on the development of anti-mPF4/heparin antibodies in vivo. BL6 mice were injected with mPF4 and UFH at various concentrations and antibodies to mPF4/heparin (mP + H) were assayed at baseline or D8 from the start of immunizations. (A) Cohorts (n = 10/cohort) were injected with mPF4 (200 μg/mL) alone or in combination with heparin at various PHRs (PHRs from left to right after PF4 alone, 26:1, 2.6:1, and 1:5). (B) Cohorts (n = 7/cohort for PF4 alone, and UFH 50 U/mL; n = 10/cohort for other conditions) were injected with mPF4 (100 μg/mL) alone or in combination with heparin at various PHRs (PHRs from left to right after PF4 alone, 20:1, 10:1, 1:1, and 1:5). Significant differences between cohorts are indicated at the top of the figures.

Effect of heparin on the development of anti-mPF4/heparin antibodies in vivo. BL6 mice were injected with mPF4 and UFH at various concentrations and antibodies to mPF4/heparin (mP + H) were assayed at baseline or D8 from the start of immunizations. (A) Cohorts (n = 10/cohort) were injected with mPF4 (200 μg/mL) alone or in combination with heparin at various PHRs (PHRs from left to right after PF4 alone, 26:1, 2.6:1, and 1:5). (B) Cohorts (n = 7/cohort for PF4 alone, and UFH 50 U/mL; n = 10/cohort for other conditions) were injected with mPF4 (100 μg/mL) alone or in combination with heparin at various PHRs (PHRs from left to right after PF4 alone, 20:1, 10:1, 1:1, and 1:5). Significant differences between cohorts are indicated at the top of the figures.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal